Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety. Credit...Blake Cale Supported by By Walt Bogdanich Carson Kessler ...

Mary Mobley is an editorial fellow in media and public relations at The Heritage Foundation. The U.S. Food and Drug Administration has approved a new abortion drug. The drug, which is a generic ...

WASHINGTON — When President Donald Trump’s administration announced it would repurpose an old, generic drug as a new treatment for autism, it came as a surprise to many experts — including the ...

Matthew Herper covers medical innovation — both its promise and its perils. Amid all the hand-shaking and back-patting, it was perhaps the word “friendship” that stood out the most when the CEO of ...

This week, President Donald Trump sought to justify his new policy of summarily executing suspected drug smugglers by declaring that his targets are "unlawful combatants" in an "armed conflict" with ...

Steve Macfarlane consults for Eisai, Janssen and Eli Lilly, and participated as a researcher in the donanemab study. Eisai manufactures lecanemab, while donanemab is owned by Eli Lilly. Dementia is a ...

Health and Human Services Secretary Robert F. Kennedy Jr. opened an investigation into the safety of the abortion pill mifepristone. The US Food and Drug Administration will conduct its own review ...

SIX. HOMELAND SECURITY OFFICIALS TODAY IDENTIFIED SIX MEN THEY SAY ARE SUSPECTS IN A HUMAN AND DRUG TRAFFICKING RING. IMMIGRATION OFFICIALS SAID THEY ARRESTED 24 PEOPLE IN MANITOWOC LAST WEEK.

A notice calls the people the U.S. military recently killed on suspicion of drug smuggling in the Caribbean Sea “unlawful combatants.” By Charlie Savage and Eric Schmitt Reporting from Washington ...

"Today, I'm thrilled to announce that one of the world's largest pharmaceutical manufacturers and one of the best anywhere in the world, Pfizer, has agreed to offer countless prescription medications ...

The drug, originally approved in 1997 by the FDA to treat male pattern baldness, has remained a staple in the dermatological toolbox, often marketed directly to young men as a low-risk, high-reward ...